Vivos Therapeutics, Inc. (VVOS) stock
VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.08−0.00 (-3.04%)
Close on Nov 17, 2026Market cap $1.60MP/E –Yield –
Vivos Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Vivos Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2023 was $300.00K, down 25.0% year over year. For fiscal 2025 it was $100.00K, up 0.0% from the year before. The highest annual figure on record is $200.00K in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.00K | 0.0% |
| FY2024 | Dec 31, 2024 | $100.00K | 0.0% |
| FY2023 | Dec 31, 2023 | $100.00K | -50.0% |
| FY2022 | Dec 31, 2022 | $200.00K | 0.0% |
| FY2021 | Dec 31, 2021 | $200.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2024 | Mar 31, 2024 | $100.00K | – |
| Q3 FY2023 | Sep 30, 2023 | $100.00K | 0.0% |
| Q2 FY2023 | Jun 30, 2023 | $100.00K | 0.0% |
| Q1 FY2023 | Mar 31, 2023 | $100.00K | 0.0% |
| Q4 FY2022 | Dec 31, 2022 | $0 | -100.0% |
| Q3 FY2022 | Sep 30, 2022 | $100.00K | 0.0% |
| Q2 FY2022 | Jun 30, 2022 | $100.00K | 0.0% |
| Q1 FY2022 | Mar 31, 2022 | $100.00K | 0.0% |
| Q4 FY2021 | Dec 31, 2021 | $100.00K | – |
| Q3 FY2021 | Sep 30, 2021 | $100.00K | – |
| Q2 FY2021 | Jun 30, 2021 | $100.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $100.00K | – |
See a number that looks wrong?